Oti

Antibiotics Don't Prevent Future Urinary Tract Infections, May Cause Resistance in Future Infections

PHILADELPHIA, July 10, 2007 /PRNewswire-USNewswire/ -- After afirst childhood urinary tract infection (UTI), daily antibioticsmay not prevent another such infection, and may actually increasethe risk that the next urinary tract infection is caused byresistant bacteria, according to a new study in the July 11 issueof the Journal of the American Medical Association. In the first larg...

Gentium's Defibrotide Seen as Active in Multiple Myeloma

NEW YORK--(BUSINESS WIRE)--Jun 27, 2007 - Gentium S.p.A. (Nasdaq:GENT) announced the presentation of both clinical and preclinicaldata that support the safety, activity, synergy and potentialmechanism of action of Defibrotide in combination with anticancertherapy in multiple myeloma. Investigators presented both an updatefrom the Company's ongoing Phase I/II clinical trial for patientswith...

Replidyne Announces Positive Phase I Results for Topical Antibiotic REP8839

LOUISVILLE, Colo., June 26, 2007 /PRNewswire-FirstCall/ --Replidyne, Inc. today announced results from three Phase I trialsstudying REP8839, a novel topical antibiotic that has shown potentin vitro activity against major skin pathogens includingmethicillin-resistant S. aureus (MRSA). The results of the Phase Itrials show that topically applied REP8839 appears safe,well-tolerated and asso...

Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide

CRANBURY, N.J., and BRISTOL, Tenn., May 22, 2007/PRNewswire-FirstCall/ -- Palatin Technologies, Inc. and KingPharmaceuticals, Inc. reported today that data from Study 16 andStudy 17 of the Phase 2B clinical trial program evaluatingbremelanotide in men with erectile dysfunction (ED) were presentedyesterday at the American Urological Association (AUA) AnnualMeeting (AUA 2007) held in Anahe...

Antipsychotic Iloperidone Results Show Favorable Akathisia Profile

SAN DIEGO, May 22, 2007 /PRNewswire-FirstCall/ -- According tostudy results presented today at the 2007 American PsychiatricAssociation annual meeting, iloperidone, an investigationalatypical antipsychotic, was shown to have a favorable akathisiaprofile. Akathisia -- a debilitating sensation of restlessness thatmanifests as an inability to sit still -- is a frequent side effectof antipsy...

FDA Announces Change of Location Notice for Upcoming Advisory Committee Meeting

ROCKVILLE, Md., April 18, 2007--Due to water damage caused byflooding over the weekend, FDA has been forced to change thelocation for the upcoming Antiviral Drugs Advisory Committeemeeting on April 24, 2007 to discuss new drug application formaraviroc 300 milligram tablets. Originally scheduled to be held atthe FDA, Center for Drug Evaluation and Research Advisory CommitteeConference Roo...

FDA Announces Results of Investigation Into Illegal Promotion of OxyContin by The Purdue Frederick Company, Inc.

Company Misrepresented Prescription PainReliever to Health Care Professionals ROCKVILLE, Md., May 10, 2007-The U.S. Food and DrugAdministration's (FDA) Office of Criminal Investigations (OCI)announced today that The Purdue Frederick Company, Inc. has agreedto pay more than $700 million to resolve criminal charges and civilliabilities in connection with...

Microbia Announces Positive Phase 2 Results for Its Investigational Compound Linaclotide

- Data being presented today at Digestive Disease Week - CAMBRIDGE, Mass., May 21, 2007 /PRNewswire/ -- Microbia todayannounced the presentation of data from a Phase 2 study in whichlinaclotide accelerated colonic transit and improved bowel functionin patients with constipation- predominant irritable bowel syndrome(IBS-C). These data also showed linaclotide was well tolerated witha low in...

New Data On the Probiotic Strain Bifantis Shows Anti-Inflammatory Properties and Increased Health Benefits

- Bifantis shows ability to limit inflammation in models ofarthritis and Salmonella infection, according to data presented atDigestive Disease Week - WASHINGTON, May 21, 2007 /PRNewswire/ -- The biotechnologycompany Alimentary Health today announced results from two studiesthat demonstrate the anti-inflammatory activity of a naturalprobiotic bacterial strain of human origin, Bifantis(R)(...

Palatin Technologies and King Pharmaceuticals Announce Plan To Present Results of Bremelanotide Phase 2b Studies in Men With Erectile Dysfunction

CRANBURY, N.J. and BRISTOL, Tenn., May 09, 2007/PRNewswire-FirstCall/ -- Palatin Technologies, Inc. and KingPharmaceuticals, Inc. today announced plans to present the resultsfrom two bremelanotide Phase 2b studies of men with erectiledysfunction (ED). The presenters are Jed Kaminetsky, MD, ClinicalAssistant Professor, Department of Urology, NYU School of Medicine;Stanley E. Althof, PhD,...

Gentium's Defibrotide Highlighted in Poster Presentation at World Congress of Nephrology

VILLA GUARDIA (COMO), Italy--(BUSINESS WIRE)--Apr 23, 2007 -Gentium S.p.A. (NASDAQ: GENT) (the "Company") today reported thatits lead product, Defibrotide, will be the subject of a posterpresentation at the World Congress of Nephrology 2007 being held inRio de Janeiro, Brazil from April 21-25, 2007. On Monday, April 23, 2007, Cinara Echart, Ph.D., Manager ofBiological Research Laboratory...

Gloucester Pharmaceuticals Reports on Romidepsin and Erlotinib Combination in Non-Small Cell Lung Cancer Presented at American Association of Cancer Research Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 18, 2007 - GloucesterPharmaceuticals, Inc., an oncology focused biopharmaceuticalcompany, announced today that encouraging data from a preclinicalstudy examining the combination of romidepsin and erlotinib innon-small cell lung cancer (NSCLC) cell lines derived from humancancer patients were presented at the American Association ofCancer Research Meeti...

Gentium's Defibrotide Highlighted in Two Poster Presentations at American Association for Cancer Research Annual Meeting

VILLA GUARDIA (COMO), Italy--(BUSINESS WIRE)--Apr 13, 2007 -Gentium, S.p.A. (NASDAQ:GENT) (the "Company") today reported thatits lead investigational product, Defibrotide, will be the subjectof two poster presentations at the American Association for CancerResearch's (AACR) Annual Meeting being held at the Los AngelesConference Center in Los Angeles, California, from April 14-18,2007. On...

Targanta Reports Improved Ability of Oritavancin to Stop Bacteria Growth In Vitro Compared With Other Glycopeptide Antibiotics

Three Oritavancin Studies Presented at ECCMID/ICC MUNICH, Germany, April 03, 2007 /PRNewswire/ -- TargantaTherapeutics today announced results from two studies showing theimproved potency of oritavancin to stop bacterial growth in vitrowhen tested with a common wetting agent (polysorbate 80) and onestudy demonstrating the activity of oritavancin against S.pneumoniae in a mouse model of pn...

New Data Show Early Non-Response to Antipsychotic Treatment May Be Strong Predictor of Subsequent Non-Response for People with Schizophrenia

Findings indicate early non-responders unlikely to subsequentlyrespond, have substantially more treatment costs, and may benefitfrom earlier change in treatment strategy COLORADO SPRINGS, Colo., April 03, 2007 /PRNewswire-FirstCall/-- New data presented at the 2007 International Congress onSchizophrenia Research (ICOSR) suggest that antipsychotic drugresponse be assessed earlier than is p...

Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and Effective Treatment to Reduce Risk of Stroke

EXACT and CAPTURE 2 Findings Suggest Improved Outcomes in CarotidArtery Stenting ABBOTT PARK, Ill., March 26, 2007 /PRNewswire-FirstCall/ --Positive 30-day results from two Abbott studies confirm thatcarotid stenting can be performed with positive results byphysicians with a variety of background experience in real-world(non-clinical trial) settings in patients who are not favorablecandi...

Corcept Therapeutics Announces Phase 3 Study Evaluating Corlux for Psychotic Major Depression Misses Primary Endpoint

STATISTICALLY SIGNIFICANT CORRELATION BETWEENPLASMA LEVELS AND CLINICAL OUTCOME ACHIEVED DURING TREATMENT Management will host a conference call and livewebcast on March 20, 2007 at 9:00 a.m. EDT MENLO PARK, Calif. (March 19, 2007) – Corcept TherapeuticsIncorporated (NASDAQ: CORT), today announced that Study 06, thelast of three Phase 3 trial...

In New Study, Duloxetine Reduced Non-specific Pain and Emotional Symptoms Associated with Depression

MADRID, Spain, 19 march 2007 - The antidepressant duloxetine, ata once-daily dose of 60 mg, significantly reduced non-specific painand emotional symptoms associated with depression in a new,eight-week, placebo-controlled study of 327 adult patients with atleast moderate pain and major depression. The results werepresented today at the 15th European Congress of Psychiatry (AEP)in Madrid,...

Data from Preclinical Studies of Gilead Nucleotide Compound GS 9219 to be Presented at AACR

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mar 15, 2007 - GileadSciences, Inc. (Nasdaq:GILD) today announced that the company willpresent data on a novel nucleotide analog, GS 9219, which has shownevidence of anti-cancer activity in preclinical studies, at the2007 Annual Meeting of the American Association for Cancer Research(AACR), which will take place in Los Angeles on April 14-18, 2007. "W...

Arpida adds novel antibiotic AR-2474 to its preclinical pipeline

In vitro microbiology and proof of concept in topical models ofinfection REINACH / BASEL, Switzerland, 8 March 2007 - Arpida Ltd.(SWX: ARPN) today announced positive results of in vitromicrobiological studies with AR-2474 against a large panel ofclinical isolates, including those resistant to various currenttherapies. In addition, topical applications of AR-2474 were foundto be hi...